› Forums › General Melanoma Community › Has Anyone Seen a Recent TimCT Post? TIL process
- This topic has 3 replies, 3 voices, and was last updated 1 year, 5 months ago by
Bubbles.
- Post
-
- June 7, 2022 at 3:00 pm
Last year TimCT posted some very helpful info about his journey through the TIL process. As of the last post I saw, he did not yet know if the treatment was having the desired result. Perhaps I’ve missed an update, or if not, I hope he hasn’t posted because he’s having a great time living a good life! Has anyone seen an update or have any new info on TIL? Thanks much!
Viewing 1 reply thread
- Replies
-
-
- June 7, 2022 at 6:48 pm
DJ22, there is a lot going on with LN-144 Iovance program as they reported on 3rd group of patients in another arm of there trial cohort #4 (see following link for data) and they also are in talks with FDA about getting final approval of biologics license application (BLA). So, in late summer company should know if they have done enough for final fDA approval in melanoma. Now, there are also other TIL programs being run at the NIH and also in Israel but there hasn’t been much news from other programs lately. Here is the link to Iovance news update. https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-announces-positive-clinical-data-
- June 8, 2022 at 3:29 pm
Ed, thank you for link to that info. I wish it was better than 29%, but it’s sure better than nothing. If I qualify, I think I’m headed in that direction if my latest treatment (Opdualag) fails. Thanks for all the info and help you provide on this site; it is very much appreciated.
-
- June 8, 2022 at 8:29 pm
Hey DJ,Probably won’t add much to what Ed has shared, but I put this together from a report out of ASCO last year. There are links to previous reports with basic TIL info within it as well – TIL – A report out of ASCO 2021 and incredible words from one of Melanoma’s Most Fearless and Inspiring Leaders
Keeping fingers crossed that Opdualag provides everything you need!!! c
-
Viewing 1 reply thread
- You must be logged in to reply to this topic.